Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation
Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation
复制标题
DOI：
10.1016/j.ajog.2011.03.028
复制
发表时间：
2011-07-01
影响因子：
9.8
通讯作者：
Harper, Margaret
中科院分区：
文献类型：
--
作者：
Caritis, Steve N.;Sharma, Shringi;Harper, Margaret
目的：研究17-羟孕酮己酸酯(17-OHPC)在多胎妊娠中的药代动力学参数。研究设计：97例双胞胎孕妇和26例三胞胎孕妇分别于孕24~28周和32~35周采血。其中6名双胞胎孕妇在怀孕24周至28周期间每天采血7天，并使用非隔室分析估计药代动力学参数。结果：17-OHPC的表观半衰期为10天。体重指数显著影响17-OHPC浓度，但胎儿数量和胎次不影响。非洲裔美国人的表观清除量显著高于白人女性(P=.025)。结论：这是17-OHPC在孕妇中的首次药代动力学分析。半衰期的测定，影响血浆17-OHPC浓度的协变量，以及药物行为的建模，为了解该药物在多胎妊娠期间的药理特性提供了深入的了解。
OBJECTIVE: The purpose of this study was to define the pharmacokinetic parameters of 17-hydroxyprogesterone caproate (17-OHPC) in multifetal gestation.STUDY DESIGN: Blood was obtained at 24-28 weeks' gestation and at 32-35 weeks gestation in 97 women with twin and 26 women with triplet gestation who were receiving 17-OHPC. Six of the women with twins had daily blood sampling for 7 days between 24 and 28 weeks' gestation, and pharmacokinetic parameters were estimated with the use of noncompartmental analysis. Modeling was applied to estimate the population parameters and to simulate various treatment scenarios.RESULTS: The apparent half-life of 17-OHPC was 10 days. Body mass index significantly impacted 17-OHPC concentrations, but fetal number and parity did not. Apparent clearance was significantly greater in African American than in white women (P = .025).CONCLUSION: This is the first pharmacokinetic analysis of 17-OHPC in pregnant women. Determination of half-life, covariates that affect plasma 17-OHPC concentrations, and the modeling of drug behavior provide insights into this drug's pharmacologic properties during multifetal pregnancy.